Portfolio data

Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022

• Late-stage clinical companies
• Autolus Therapeutics

Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022

• Operating News
• Clinical companies
• Anaveon

New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B

• Operating News

Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Association Congress

Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022

• Clinical companies
• Anaveon